Sugi Predict

Sugi Predict / Compounds / SCHEMBL908134

SCHEMBL908134

SCHEMBL908134

CCOC(=O)C1CCCc2sc(N)nc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.45
▸ KDM4E B2RXH2 4/20 0.45
▸ GAA P10253 4/20 0.45
▸ HSD17B10 Q99714 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ RECQL P46063 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ PDK1 Q15118 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ HPGD P15428 4/20 0.39
▸ MAPT P10636 3/20 0.39
▸ ALOX15 P16050 2/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ADRB3 P13945 2/20 0.38
▸ LIMK1 P53667 1/20 0.38
▸ PARP1 P09874 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ TLR4 O00206 1/20 0.36
▸ TSHR P16473 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19674285 1.00 ALDH1A1 (0.45) ALDH1A1KDM4EGAAHSD17B10MEN1
Bromide SCHEMBL4802784 0.99 ALDH1A1 (0.44) ALDH1A1KDM4EGAAHSD17B10MEN1
SCHEMBL1155828 0.92 ALDH1A1 (0.53) ALDH1A1KDM4EGAAHSD17B10MEN1
SCHEMBL909067 0.86 ALDH1A1 (0.46) ALDH1A1KDM4EGAAHSD17B10MEN1
SCHEMBL3929167 0.85 ALDH1A1 (0.45) ALDH1A1KDM4EGAAHSD17B10MEN1
SCHEMBL3539842 0.82 ADRA2A (0.43) ALDH1A1KDM4EGAAHSD17B10MEN1
SCHEMBL11964108 0.80 ADRB3 (0.40) GAAHSD17B10SMN1; SMN2MAPTALOX15
SCHEMBL13314787 0.80 PARP1 (0.44) ALDH1A1KDM4EGAAHSD17B10MEN1
SCHEMBL3539844 0.80 PARP1 (0.44) ALDH1A1KDM4EGAAHSD17B10MEN1
SCHEMBL3165729 0.80 ALDH1A1 (0.38) ALDH1A1KDM4EGAAHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034093-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUMITOMO PHARMA AMERICA, INC. (US) 2026-02-05 — — US disclosed
US-20240358675-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUMITOMO PHARMA AMERICA, INC. (US) 2024-10-31 — — US disclosed
CN-118165002-A Polycyclic compounds and methods of use thereof 桑诺维恩药品公司 2024-06-11 — — CN disclosed
EP-3252057-B1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2024-03-27 — — EP disclosed
US-20220387382-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2022-12-08 — — US disclosed
US-20220387382-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2022-12-08 — — US disclosed
US-10894033-B2 Multicyclic compounds and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2021-01-19 — — US disclosed
US-10894033-B2 Multicyclic compounds and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2021-01-19 — — US disclosed
US-20200323819-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2020-10-15 — — US disclosed
US-20200323819-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2020-10-15 — — US disclosed
EP-1723128-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2006-11-22 — — EP disclosed
US-7112590-B2 Thrombin inhibitors LEK PHARMACEUTICALS D.D. (SI) 2006-09-26 — — US disclosed
US-20060205744-A1 Fused heterocyclic derivatives as ppar modulators ELI LILLY AND COMPANY PATENT DIVISION (US) 2006-09-14 — — US disclosed
EP-1585726-A1 FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-10-19 — — EP disclosed
WO-2005066145-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2005-07-21 — — WO disclosed
EP-1287018-B1 THROMBIN INHIBITORS LEK TOVARNA FARMACEVTSKIH (SI) 2005-01-19 — — EP disclosed
WO-2004063155-A1 FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-07-29 — — WO disclosed
US-20030191139-A1 Thrombin inhibitors UNIVERSITY OF LJUBLJANA (SI) 2003-10-09 — — US disclosed
EP-1287018-A2 THROMBIN INHIBITORS Lek Pharmaceutical and Chemical Co. D.D. (SI) 2003-03-05 — — EP disclosed
WO-2001085760-A1 THROMBIN INHIBITORS LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) 2001-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191139-A1 Thrombin inhibitors TFPI, F2, SERPINC1 ALDH1A1 2395/4885KDM4E 3728/4885GAA 2035/4885
US-20060205744-A1 Fused heterocyclic derivatives as ppar modulators PPARA, PPARG, PPARD ALDH1A1 1401/4885KDM4E 2426/4885GAA 4154/4885
US-20220387382-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF GRIN2C, NLN, COMT ALDH1A1 919/4885KDM4E 4068/4885GAA 532/4885
US-20200323819-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF GRIN2C, NLN, COMT ALDH1A1 919/4885KDM4E 4068/4885GAA 532/4885
US-20240358675-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF GRIN2C, NLN, COMT ALDH1A1 919/4885KDM4E 4068/4885GAA 532/4885
US-10894033-B2 Multicyclic compounds and methods of use thereof GRIN2C, NLN, COMT ALDH1A1 919/4885KDM4E 4068/4885GAA 532/4885
US-20260034093-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SLC6A3, SLC6A11, SLC6A13 ALDH1A1 1362/4885KDM4E 3102/4885GAA 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.